Cancer BiologybioRxivPreprint
Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner
K. K. Mahadevan, K. McAndrews, V. LeBleu…·R. Kalluri
This study shows that MRTX1133, a KrasG12D inhibitor, reduces early pancreatic lesions and, when combined with immunotherapy, regresses advanced PDAC by enhancing CD8+ T cell activity.
DOI 10.1101/2023.02.15.528757